Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine added to standard treatment for aluminum phosphide poisoning
IRCT20211017052794N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trimetazidine in Aluminium phosphide poisoning (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Hospital mortality, Need for ICU and 1 more. Started Sep 2022; status: completed.
02
Drugs
trimetazidine
03
Conditions
Aluminium phosphide poisoning
Beyond the preview
Go deeper on IRCT20211017052794N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211017052794N1.